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Abstract  
 
Background Irinotecan plus S-1  (IRIS) is the only oral fluoropyrimidine-based 
regimen reported to be non-inferior to FOLFIRI and widely used in clinical practice for 
metastatic colorectal cancer (mCRC) patients. However, the combination of IRIS plus an 
anti-EGFR agent has not been evaluated previously. This study aimed to investigate the 
feasibility and efficacy of IRIS with panitumumab as second-line therapy for wild-type 
KRAS mCRC. 
Methods Main inclusion criteria were patients with wild-type KRAS mCRC refractory to 
one prior chemotherapy regimen for mCRC, ECOG PS 0-2, and age ≥ 20 years. Patients 
received panitumumab (6mg/kg) and irinotecan (100mg/m2) on days 1 and 15 and S-1 
(40-60 mg according to body surface area) twice daily for 2 weeks, repeated every 4 
weeks. The primary endpoint was the feasibility of the therapy. The secondary endpoints 
were response rate (RR), progression-free survival (PFS), and overall survival (OS).  
Results A total of 36 patients received protocol treatment in eight centers. Of these, 23 
patients (63.9%) completed protocol treatment, demonstrating achievement of the 
primary endpoint. The most frequent grade 3/4 toxicities were diarrhea (16.7%), acne-
like rash (13.9%), and neutropenia (11.1%). The overall RR was 33.3% (12/36). Of these 
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five underwent conversion surgery. Median PFS and OS were 9.5 months (95% CI 3.5-
15.4 months) and 20.1 months (95% CI 16.7-23.2 months), respectively. 
Conclusion IRIS plus panitumumab has an acceptable toxicity profile and a promising 
efficacy in patients with previously treated wild-type KRAS mCRC. Accordingly, this 
regimen can be an additional treatment option for second-line chemotherapy in wild-type 
KRAS mCRC. 
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Introduction 
 
 Colorectal cancer (CRC) is the third most common cancer worldwide, with up 
to 1 million new cases diagnosed each year [1]. Surgical resection is the only curative 
therapy for CRC. However, approximately 25% of patients present with metastases at 
initial diagnosis, and almost 50% of patients with CRC will develop metastases, 
contributing to the high mortality rates reported for CRC [2]. Recently, the outcome of 
patients with metastatic colorectal cancer (mCRC) has clearly improved with a median 
survival now reaching nearly 30 months in clinical trials. This improvement is largely due 
to the development of new chemotherapeutic agents. Combinations of the cytotoxic 
agents with 5-fluorouracil (5-FU) in 5-FU/leucovorin (LV) /oxaliplatin (FOLFOX) or 5-
FU/LV/irinotecan (FOLFIRI) have been established as the standard chemotherapy for 
mCRC. Moreover, the introduction of monoclonal antibodies against vascular endothelial 
growth factor (VEGF) and epidermal growth factor receptor (EGFR) has significantly 
improved the outcome of patients with mCRC. In these circumstances, approximately 
70% of patients who progress after the first line of chemotherapy will receive at least one 
subsequent line of systemic treatment [3]. This indicates the growing importance of 
exploring an optimal second-line treatment strategy for mCRC. 
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 Panitumumab is a fully humanized antibody that binds to EGFR and prevents 
receptor dimerization, tyrosine autophosphorylation of EGFR, and the activation of 
downstream signaling molecules. Tumor KRAS status predicts the efficacy of anti-EGFR 
agents in mCRC patients and is a well-established biomarker for patient selection [4-6]. 
Several lines of evidence have shown that panitumumab is active in different lines of 
treatment and in various combinations with chemotherapy. Peeters and colleagues 
demonstrated that panitumumab significantly improved the progression-free survival 
(PFS) in combination with FOLFIRI in second-line treatment of patients with wild-type 
KRAS mCRC [7]. 
The FOLFOX or FOLFIRI regimens include continuous infusion of fluorouracil, 
therefore, both of them require implantation of an intravenous port system, which 
sometimes causes problems such as infection and thrombosis. Muro and colleagues 
performed a phase II/III randomized study (FIRIS study) to compare irinotecan plus oral 
fluoropyrimidine, S-1 (a combination of tegafur, 5-chloro-2,4-dihydroxipyridine, and 
potassium oxonate; IRIS) with FOLFILI as second-line chemotherapy for mCRC, and 
showed non-inferiority of IRIS to FOLFIRI in terms of efficacy and safety [8]. This 
enabled the choice of second-line chemotherapy without continuous infusion. However, 
there has been no previous clinical trial published that investigated safety and efficacy of 
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IRIS plus an anti-EGFR agent for mCRC. Therefore, in this study, we conducted a 
prospective, phase II, multicenter trial to investigate the tolerability and efficacy of 
combination therapy with IRIS plus panitumumab as second-line chemotherapy in 
patients with wild-type KRAS mCRC. 
 
Patients and methods 
 
Study design and eligibility 
 
 This study was a multicenter, non-randomized, open-label phase II trial 
undertaken in eight hospitals (UMIN-CTR registration No. UMIN000004659). The 
primary endpoint was the feasibility of the therapy. The secondary endpoints were overall 
response rate (RR), PFS, overall survival (OS), and toxicity. We set feasibility as primary 
endpoint because it was important to evaluate tolerability and safety profile for 
subsequent phase 3 study at the time when this study was conducted. The study was 
performed according to the Declaration of Helsinki and was approved by the independent 
ethics committees at participating study centers. 
Inclusion criteria were: histologically confirmed colorectal adenocarcinoma with 
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wild-type KRAS; unresectable metastatic disease; age ≥ 20 years; Eastern Cooperative 
Oncology Group (ECOG) performance status of 0 or 1; presence of at least one 
measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 
criteria (ver.1.1) [9] ; withdrawal from first-line chemotherapy due to progressive disease 
or toxicity, or relapse within 24 weeks after the final dose of preoperative or postoperative 
chemotherapy; no previous treatment with irinotecan or anti-EGFR agent; sufficient oral 
intake ability; adequate organ function (hemoglobin ≥ 10 g/dl, leukocytes 3,000-12,000 
cells/mm3, platelets ≥ 100,000/mm3, serum total bilirubin ≤ 1.5 mg/dl, serum 
transaminases (aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 
100 IU/L), serum creatinine ≤ 1.2 mg/dl); and no abnormal electrocardiographic findings 
within 28 days before enrollment. Exclusion criteria were watery diarrhea; uncontrolled 
pleural effusion or ascites; active infection; active gastroduodenal ulcer; severe 
complications such as heart disease or renal disease; mental disorder; history of interstitial 
pneumonia and pulmonary fibrosis; history of drug hypersensitivity; active concomitant 
malignancy; and pregnant and lactating females. 
 
Treatment schedule  
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 S-1 was administered orally twice daily for 14 consecutive days, followed by a 
14-day rest. The actual dosage of S-1 was decided according to the patient’s body surface 
area [BSA] (40 mg for patients with BSA <1.25 m2; 50 mg for patients with 1.25 < BSA 
<1.5 m2; 60 mg for patients with BSA ≥ 1.5 m2). Six mg/kg of panitumumab and 100 
mg/m2 of irinotecan were administered as continuous infusions on days 1 and 15. In 
previous phase2/3 study of the IRIS, irinotecan was administered at a dose of 125 mg/m2 
[8]. However, as adverse drug reactions were intense at that irinotecan dose []125 mg/m2] 
in IRIS, recent studies of a combination of IRIS with a biological targeted agent have 
been conducted at a dose of 100 mg/m2 [10,11]. Therefore, we chose an irinotecan dose 
of 100 mg/m2 in this study. This 28-day cycle was defined as one course of treatment. 
Initiation of a treatment cycle and administration of irinotecan on day 15 required that 
neutropenia and thrombocytopenia were grade 2 or lower and non-hematologic toxicities 
were grade 1 or lower. Administration of panitumumab required confirmation of grade 2 
or lower electrolyte abnormalities including hypomagnesemia, hypocalcemia and 
hypokalemia and grade 2 or lower skin toxicities including pruritus, acneiform dermatitis, 
skin desquamation, nail disorder, skin fissures, skin laceration, and paronychia. All 
patients received pre-emptive skin treatment consisting of skin moisturizer applied to face 
and body daily; topical steroid (0.1% hydrocortisone butyrate applied to face; 0.05% 
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difluprednate applied to body); and minocycline 100 mg twice per day.  
 When the patients were judged as resectable after tumor shrinkage by the 
treatment, they underwent conversion surgery. Protocol chemotherapy was discontinued 
in the event of disease progression, conversion surgery, unacceptable adverse events, 
patient’s refusal to the treatment, withdrawal of consent, or by physician’s decision. A 
completion of treatment was defined as continuing the protocol treatment until disease 
progression or until the patient had undergone conversion surgery. 
 
 Toxicity and efficacy 
 
Patients who received at least one treatment course were included in toxicity and efficacy 
analyses. Medical history, physical examination, and safety evaluation were performed 
prior to treatment and biweekly thereafter. Laboratory tests were also obtained biweekly 
or more frequently in cases of severe toxicities, and always prior to treatment with 
irinotecan and panitumumab. Toxicity was assessed according to the Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.0. CT scanning was 
performed at 8-week intervals after the start of treatment to assess tumor response in 
accordance with the RECIST. PFS was defined as the time from registration until 
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objective tumor progression or death. If the patient underwent conversion surgery, PFS 
was measured from registration to the date of progression or death after surgery. OS was 
defined as the time from registration until death from any cause.  
 
Statistical analysis 
 
 On the basis of the data from the FIRIS study that more than 23% of the patients 
who received IRIS discontinued protocol treatment because of adverse events or patient 
refusal, the expected completion rate was determined to be 75%. In order to confine the 
95% confidence interval to +/-15%, the required number of patients was calculated to be 
32. Thus, the feasibility was defined as exceeding the lowest rate of the range of 
completion rate (60%). The target number of patients was set at 35, including 10% of 
dropouts and excluded patients. PFS and OS were calculated by the Kaplan-Meier method 
from the date of enrollment.  
 
Results 
 
Patient characteristics 
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 A total of 37 patients were enrolled in this study between January 2011 and 
November 2013. One patient was not eligible because of his worsening performance 
status, and 36 patients received more than one planned treatment with IRIS plus 
panitumumab; they were analyzed for safety and efficacy. Their demographic data are 
summarized in Table 1. They comprised 24 men and 12 women, with a median age of 65 
years (range: 33-84 years). ECOG PS was 0 in 30 patients and 1 in 6 patients. Nineteen 
patients (52.7%) had liver metastases, 13 (36.1%) lung metastases, 6 (16.7%) lymph node 
metastases, and 3 (8.3%) peritoneal metastases. Twelve patients were heterozygous for 
uridine diphosphate-glucuronosyltransferase1A1 (UGT1A1) *6 or UGT1A1*28, one 
patient was homozygous for UGT1A1*6, and one was heterozygous for both UGT1A1*6 
and UGT1A1*28. The median follow-up time was 18.5 months (range, 1.4 – 38.5 
months). 
 
Treatment exposure 
 
 The median number of treatment cycles was 5 (range, 1 to 18 cycles). Treatment 
delay and dose reduction occurred in 25 patients (69.4%). Diarrhea was the most frequent 
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cause of treatment delay, and skin toxicity was a major cause of dose reduction (26.9% 
and 36.4%, respectively). Treatment was discontinued because of disease progression in 
18 patients (50%), conversion to surgery in 5 (13.9%), adverse events in 4 (11.1%), and 
patient refusal to continue or other reasons in 9 patients (25%). Overall 63.9% (23/36) of 
patients have completed their protocol treatment, indicating that this study met the 
primary endpoint. The median relative dose intensities to the planned dose were 88.8% 
for S-1, 84.8% for irinotecan, and 85.6% for panitumumab, respectively. Adverse events 
leading to withdrawal in 4 patients were mainly associated with skin toxicity.  
 
Toxicity 
 
All 36 patients were evaluated for toxicity. Table 2 summarizes the treatment-
related clinical adverse events. The major grade 3 or 4 adverse events were diarrhea 
(16.7%), acne-like rash (13.9%), decreased appetite (11.1%), and neutropenia (11.1%). 
Two patients (5.6%) experienced febrile neutropenia although both of them recovered in 
a few days by treatment with granulocyte colony-stimulating factor and antibiotics. Most 
patients (35/36) experienced skin toxicities including paronychia, acne-like rash, and skin 
laceration. However, the majority of these were grade 2 or lower. Other treatment-
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associated symptoms were infrequent or negligible, and there were no treatment related 
deaths. 
 
Efficacy 
 
 Tumor responses are summarized in Table 3. Among the 36 patients, one patient 
achieved complete response (CR), 11 experienced partial response (PR), 19 had stable 
disease (SD) and 2 had progressive disease (PD). Three patients were not evaluable for 
treatment response due to symptomatic deterioration prior to radiological response 
evaluation. On a per-protocol basis, the response rate (CR + PR) was 33.3%, and the 
disease control rate (CR + PR + SD) was 86.1%. The median time to response was 63 
days [95% confidence interval (CI) 49.6-76.4 days] for patients who responded (CR or 
PR). Five patients underwent conversion surgery because the physician decided that the 
metastatic lesion was resectable. Surgical curability types were R0 in one patient, R1 in 
2 patients, and R2 in 2 patients. The median PFS was 9.5 months (95% CI 3.5 – 15.4 
months) and median OS was 20.1 months (95% CI 16.7 – 23.2 months) (Figure 1A and 
B).  
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Discussion 
 
In this phase II study, we demonstrated that our combination therapy with IRIS 
plus panitumumab was well tolerated and had a promising efficacy against wild-type 
KRAS mCRC as a second-line treatment. To our knowledge, this is the first report to 
evaluate IRIS plus anti-EGFR antibodies prospectively. The most common reason for 
treatment discontinuation was disease progression, which occurred in 50 % (18/36) of 
patients. Five patients (13.9 %) experienced remarkable tumor shrinkage during their 
protocol treatment and could undergo conversion surgery. Overall 63.9 % (23/36) of 
patients have completed their protocol treatment, indicating that this study met the 
primary endpoint. Although this value is relatively low, the previous completion rates of 
IRIS and FOLFIRI plus panitumumab as second-line therapy for CRCs were 74 and 59 %, 
respectively, similar to our result (63.9 %). Thus, tolerability and safety profile of IRIS 
plus panitumumab in this study were similar to those in previous reports on IRIS or 
FOLFIRI plus panitumumab as second-line therapy in patients with wild-type KRAS 
mCRC. 
The objective response rate was 33.3 %, which was similar to those (23–35 %) 
in the wild-type KRAS population receiving FOLFIRI plus panitumumab in the previous 
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studies [7, 12]. Besides, 84 % of the disease control rate in this study was relatively higher 
than those (64–74 %) of FOLFIRI plus panitumumab in the previous studies on FOLFIRI 
plus panitumumab. In addition, median PFS (9.5 months) and OS (20.1 months) were 
considerably longer than those of FOLFIRI plus panitumumab (5.9–6.4 and 12.5–14.5 
months, respectively) as second-line treatment in previous studies [7, 12]. 
In our study, the most common grade 3 or 4 hematological adverse event was neutropenia 
(11.1 %), which was relatively milder than that of the FOLFIRI plus panitumumab 
regimen in previous reports [7, 12]. On the other hand, the incidence of gastrointestinal 
adverse events including diarrhea, appetite loss, and stomatitis was relatively high, 
although severe events (grade 3 or 4) were not frequent. In general, oral fluorouracil 
agents have been shown to be associated with a higher incidence of gastrointestinal 
toxicities [13–16]. This might also be applicable to IRIS plus panitumumab. However, it 
was suggested that all gastrointestinal adverse events of this regimen were controlled by 
appropriate supportive care or treatment interruptions. Twelve patients (33.3 %) 
experienced Grade 3 skin-related toxicities including acne-like rash, cutaneous dryness, 
and paronychia. Our data indicate that the IRIS plus panitumumab regimen increase 
neither the incidence nor the severity of skin-related toxicities compared to those of 
FOLFIRI plus panitumumab regimen. 
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From the point of convenience for the patients, there has been a substantial 
demand for replacing infusional fluorouracil-based regimens with oral fluorouracil agents. 
Randomized studies comparing FOLFOX with capecitabine, another oral fluorouracil 
agent, plus oxaliplatin (CAPOX) in patients with mCRC showed non-inferiority of 
CAPOX to FOLFOX [13, 17]. In contrast, it has been reported that capecitabine plus 
irinotecan (CapeIRI) was associated with a higher incidence of gastrointestinal toxicities 
and hand–foot syndrome and PFS with CapeIRI (5.8 months) was clearly shorter than 
that with FOLFIRI (7.6 months) as first-line chemotherapy for mCRC [18]. Moreover, 
capecitabine is not recommended in combination with anti-EGFR antibodies because the 
efficacy of capecitabine-based regimens could not consistently be confirmed when they 
were combined with anti-EGFR antibodies, and increased anti-EGFR agent-related side 
effects, such as skin toxicities, occurred [19]. Thus, IRIS is the only reasonable candidate 
among oral fluorouracilbased regimens that could be combined with anti-EGFR antibody. 
Since the IRIS regimen does not include continuous infusion of fluorouracil, IRIS plus 
panitumumab provides a great advantage to patients over FOLFIRI plus panitumumab. 
However, tolerance to S-1 is thought to differ in Asian and Caucasian populations. 
Especially, gastrointestinal toxicities such as diarrhea appear to be more frequent in North 
American than in Asian [20, 21]. In the current study, all participants were Asian, and this 
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ethnic uniformity in the patient background is one of the limitations in this study. 
In conclusion, the results of this phase II study demonstrated that the 
combination of IRIS and panitumumab had an acceptable toxicity profile and a promising 
efficacy in patients with previously treated wild-type KRAS mCRC. This combination 
can be an additional treatment option for second-line chemotherapy of mCRC. 
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Table 1. Baseline demographic and clinical characteristics of patients  
Characteristics No. of patients (n = 36) % 
Gender    
    Male 24 66.7 
    Female 12 33.3 
Age (years)   
    Median (range) 65  〔33-84〕  
ECOG performance status   
    0 30 83.3 
    1 6 16.7 
Primary lesion     
    Absent   23 63.9 
    Present   13 36.1 
Metastasis   
    Liver 19 52.8 
    Lung 13 36.1 
    Lymph nodes 6 16.7 
    Peritoneal 3 8.3 
    Bone 1 2.8 
    Adrenal gland 1 2.8 
Prior chemotherapy (cytotoxic agents)   
    CAPOX   21 58.3 
    FOLFOX   13 36.1 
    5-FU/LV   1 2.8 
    Other   1 2.8 
Prior chemotherapy with bevacizumab   
    Yes   31 86.1 
    No   5 13.9 
UGT1A1 polymorphysm     
    Wild type   21 58.3 
    Hetero type                -/*6    -/-     7 19.4 
                                       -/-      -
/*28 
5 13.9 
    Double hetero type  -/*6    -
/*28 
1 2.8 
    Homo type               *6/*6    -/- 1 2.8 
    Unknown     1 2.8 
ECOG, Eastern Cooperative Oncology Group;  
CAPOX, capecitabine/oxaliplatin; FOLFOX, fluorouracil/leucovolin/oxaliplatin; 
UGT1A1, uridine diphosphate-glucuronosyltransferase 1A1. 
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Table 2. Adverse events related to IRIS plus panitumumab occuring in 
≥5% of patients treated for metastatic colorectal cancer 
Hematological events,  n  (%) Any Grades Grade  ≥3 
  Leukopenia 10  (27.7) 2  (5.6) 
  Neutropenia 9   (25.0) 4  (11.1) 
  Febrile  neutropenia 2    (5.6) 2  (5.6) 
  Anemia 14  (38.8) 1  (2.8) 
  Thrombocytopenia 8   (22.2) 1  (2.8) 
Non-hematological events, n (%) Any Grades Grade  ≥3 
  Diarrhea 22  (61.1) 6  (16.7) 
  Decreased  appetite 22  (61.1) 4  (11.1) 
  Stomatitis 21  (58.3) 3  (8.3) 
  Acne-like  rash 17  (47.2) 5  (13.9) 
  Hypomagnesemia 12  (33.3) 2  (5.6) 
  Fatigue 10  (27.7) 2  (5.6) 
  Cutaneous  dryness 10  (27.7) 2  (5.6) 
  Hypoalbuminaemia 8   (22.2) 1  (2.8) 
  Rash 7   (19.4) 3  (8.3) 
  Paronychia 7   (19.4) 3  (8.3) 
  Dehydration 7   (19.4) 1  (2.8) 
  Elevated AST 7   (19.4) 0  (0.0) 
  Elevated ALT 6   (16.7) 0  (0.0) 
  Hypocalcemia 5   (13.9) 1  (2.8) 
AST, aspartate aminotransferase; ALT, alanine aminotransferase 
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Table 3. Objective responses of patients with metastatic colorectal cancer receiving IRIS plus 
panitumumab  
 Response   
No. of patients CR PR SD PD NE RR (%) DCR (%) 
36 1 11 19 2 3 33.3 86.1 
CR; complete response, PR; partial response, SD; stable disease, PD; progression disease, RR; 
response rate, DCR; disease control rate 
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Figure legend 
Fig. 1  
Kaplan-Meier curve of (A) progression-free survival and (B) overall survival for 36 
patients. The median progression-free survival and overall survival were 9.5 months (95% 
confidence interval, 3.5-15.4 months) and 20.1 months (95% confidence interval, 16.7-
23.2 months), respectively. 
 
